Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice

Survival rate for pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is poor, with about 80% of patients presenting with the metastatic disease. Gemcitabine, the standard chemotherapeutic agent for locally advanced and metastatic PDAC has limited efficacy, attributed to innate/acquired resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwegyir-Afful, Andrew K., Murigi, Francis N., Purushottamachar, Puranik, Ramamurthy, Vidya P., Martin, Marlena S., Njar, Vincent C.O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581036/
https://www.ncbi.nlm.nih.gov/pubmed/28881737
http://dx.doi.org/10.18632/oncotarget.14154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581036/
https://www.ncbi.nlm.nih.gov/pubmed/28881737
http://dx.doi.org/10.18632/oncotarget.14154

Ejemplares similares